Larimar Therapeutics Reports Second Quarter 2025 Financial Results
LMTX*Pro forma cash, cash equivalents, and marketable securities of $203.6 million reflects $138.5 million of cash, cash equivalents and marketable securities as of June 30, 2025 combined with the $65.1 million in net proceeds from the recently completed July 2025 public offering.
August 14, 2025Earnings
Read more →